Skip to main content

Advertisement

Table 1 Clinicopathological features for 164 metastatic breast cancer patients

From: The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004–2014)

  Total patients
(n = 164)
FOXA1-positive
(n = 86)
FOXA1-negative
(n = 52)
P-value Nestin-positive
(n = 26)
Nestin-negative
(n = 114)
P-value
Age (y)     0.21    0.29
  ≤ 55 59 (36%) 22 (26%) 20 (38%)   10 (38%) 33 (29%)  
 56–80 94 (57%) 59 (69%) 28 (33%)   16 (62%) 72 (63%)  
  > 80 11 (7%) 5 (6%) 4 (5%)   0 (0%) 9 (8%)  
Metastasic site     0.31    0.06
 Abdomen/GI tract/Liver 44 (27%) 29 (34%) 9 (17%)   5 (19%) 34 (30%)  
 Axillary lymph node/sentinel node 11 (7%) 5 (6%) 3 (6%)   1 (4%) 7 (6%)  
 Brain 29 (18%) 7 (8%) 9 (17%)   8 (31%) 9 (8%)  
 Cervical lymph nodes 3 (2%) 2 (2%) 1 (2%)   0 (0%) 3 (3%)  
 Gynecological site 9 (5%) 2 (2%) 7 (13%)   2 (8%) 7 (6%)  
 Skeleton 37 (23%) 20 (23%) 15 (29%)   3 (12%) 32 (28%)  
 Skin 11 (7%) 7 (8%) 4 (8%)   3 (12%) 8 (7%)  
 Thorax/Lung 20 (12%) 14 (16%) 4 (8%)   4 (15%) 14 (12%)  
 Not available 0 (0%) 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
GATA3 status     2.80E-04    0.039
 Positive 154 (94%) 86 (100%) 44 (85%)   22 (85%) 110 (96%)  
 Negative 10 (6%) 0 (0%) 8 (15%)   4 (15%) 4 (4%)  
 Not available 0 (0%) 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
Mammoglobin status     0.080    0.83
 Positive 84 (51%) 47 (55%) 20 (38%)   12 (46%) 57 (50%)  
 Negative 80 (49%) 39 (45%) 32 (62%)   14 (54%) 57 (50%)  
 Not available 0 (0%) 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
FOXA1 status        0.0039
 Positive 86 (52%)   9 (35%) 77 (68%)  
 Negative 52 (32%)   17 (65%) 35 (31%)  
 Not available 26 (16%)   0 (0%) 2 (2%)  
Nestin status     0.0017    
 Positive 26 (16%) 9 (10%) 17 (33%)   
 Negative 114 (70%) 77 (90%) 35 (67%)   
 Not available 24 (15%) 0 (0%) 0 (0%)   
Primary tumor differentiation     0.29    0.96
 Well 10 (6%) 5 (6%) 3 (6%)   1 (4%) 7 (6%)  
 Moderate 49 (30%) 31 (36%) 11 (21%)   7 (27%) 36 (32%)  
 Poor 59 (36%) 27 (31%) 19 (37%)   9 (35%) 37 (32%)  
 Not available 46 (28%) 23 (27%) 19 (37%)   9 (35%) 34 (30%)  
Axillary lymph node status     0.047    1.00
 pN0 55 (34%) 34 (40%) 11 (21%)   9 (35%) 37 (32%)  
 pN1 78 (48%) 38 (44%) 26 (50%)   12 (46%) 53 (46%)  
 Not available 31 (19%) 14 (16%) 15 (29%)   5 (19%) 24 (21%)  
ER status     2.09E-05    0.024
 Positive 115 (70%) 74 (86%) 27 (52%)   14 (54%) 89 (78%)  
 Negative 49 (30%) 12 (14%) 25 (48%)   12 (46%) 25 (22%)  
 Not available 0 (0%) 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
PR status     0.07    0.50
 Positive 57 (35%) 39 (45%) 15 (29%)   8 (31%) 46 (40%)  
 Negative 107 (65%) 47 (55%) 37 (71%)   18 (69%) 68 (60%)  
 Not available 0 (0%) 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
HER2/neu status     0.0031    0.42
 Positive 45 (27%) 29 (34%) 6 (12%)   4 (15%) 31 (27%)  
 Negative 116 (71%) 55 (64%) 46 (88%)   22 (85%) 81 (71%)  
 Not available 3 (2%) 2 (2%) 0 (0%)   0 (0%) 2 (2%)  
Triple negative status     1.92E-06    0.0021
 Triple negative 27 (16%) 4 (5%) 19 (37%)   10 (38%) 13 (11%)  
 Non-triple negative 137 (84%) 82 (95%) 33 (63%)   16 (62%) 101 (89%)  
 Not available 0 (0%) 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
Overall survival     0.17    1.00
 Deceased 88 (54%) 68 (79%) 46 (88%)   22 (85%) 94 (82%)  
 Survivor 76 (46%) 18 (21%) 6 (12%)   4 (15%) 20 (18%)  
  1. NOTE: P-values were calculated using the Fisher's exact test (FOXA1-positive vs. FOXA1-negative or Nestin-positive vs Nestin-negative. Statistically significant variables (p <0.05) are displayed in bold text